NYSE - Nasdaq Real Time Price USD

Ginkgo Bioworks Holdings, Inc. (DNA)

Compare
6.23 -0.09 (-1.42%)
At close: September 16 at 4:00 PM EDT
6.19 -0.04 (-0.64%)
After hours: September 16 at 7:44 PM EDT
Loading Chart for DNA
DELL
  • Previous Close 6.32
  • Open 6.31
  • Bid 6.23 x 800
  • Ask 6.29 x 1000
  • Day's Range 6.03 - 6.69
  • 52 Week Range 5.26 - 82.80
  • Volume 1,856,951
  • Avg. Volume 1,649,370
  • Market Cap (intraday) 351.236M
  • Beta (5Y Monthly) 1.07
  • PE Ratio (TTM) --
  • EPS (TTM) -18.00
  • Earnings Date Aug 8, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 36.80

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

www.ginkgobioworks.com

1,218

Full Time Employees

December 31

Fiscal Year Ends

Recent News: DNA

View More

Performance Overview: DNA

Trailing total returns as of 9/16/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

DNA
90.78%
S&P 500
18.10%

1-Year Return

DNA
91.93%
S&P 500
26.58%

3-Year Return

DNA
98.46%
S&P 500
25.72%

5-Year Return

DNA
98.53%
S&P 500
35.30%

Compare To: DNA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DNA

View More

Valuation Measures

Annual
As of 9/13/2024
  • Market Cap

    351.24M

  • Enterprise Value

    73.13M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.71

  • Price/Book (mrq)

    0.42

  • Enterprise Value/Revenue

    0.40

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -22.30%

  • Return on Equity (ttm)

    -76.83%

  • Revenue (ttm)

    184.34M

  • Net Income Avi to Common (ttm)

    -897.68M

  • Diluted EPS (ttm)

    -18.00

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    730.37M

  • Total Debt/Equity (mrq)

    54.29%

  • Levered Free Cash Flow (ttm)

    -167.4M

Research Analysis: DNA

View More

Company Insights: DNA

Research Reports: DNA

View More

People Also Watch